Skip to main content

Table 4 Effects of chemotherapy on overall survival (OS) of various patient subsets.

From: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

  Factors N HR 95% CI p value
After IPTW All factors 91 3.44 2.03 - 5.83 <0.001
Age (years) <58 44 2.93 1.46 - 5.85 0.002
  ≥58 47 8.10 3.17 - 20.67 <0.001
Gender Male 67 4.97 2.69 - 9.18 <0.001
  Female 24 3.47 1.19 - 10.13 0.023
ECOG PS 0/1 54 3.93 2.03 - 7.63 <0.001
  ≥ 2 33 4.55 1.64 - 12.65 0.004
Primary site Duodenum 71 3.10 1.76 - 5.44 <0.001
  Jejunoileum* 20 NA   0.122
Histology WD/MD 44 7.63 3.01 - 19.36 <0.001
  Undifferentiated 38 2.76 1.35 - 5.66 0.006
Status Recurrent 17 7.33 1.64 - 32.75 0.009
  Metastatic 70 3.97 2.17 - 7.27 <0.001
Primary tumor Resected 29 13.49 3.48 - 52.36 <0.001
  Still present 62 2.61 1.44 - 4.75 0.002
No. of Metastases 1 50 6.13 2.96 - 12.71 <0.001
  >1 37 3.21 1.40 - 7.38 0.006
Liver metastasis Yes 39 4.29 1.65 - 9.43 <0.001
  No 52 5.34 2.52 - 11.31 <0.001
Peritoneal metastasis Yes 42 7.37 2.98 - 18.27 <0.001
  No 49 3.16 1.64 - 6.09 0.001
IALN metastasis Yes 41 3.06 1.36 - 6.89 0.007
  No 50 5.22 2.56 - 10.65 <0.001
Lung metastasis Yes 6 NA   0.486
  No 85 4.53 2.62 - 7.82 <0.001
Bone metastasis Yes 3 NA   0.809
  No 88 4.6 2.78 - 7.92 <0.001
  1. * Deaths: 8/8 in the patient group not receiving chemotherapy; 7/12 in the patient group treated with chemotherapy.
  2. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; WD, well-differentiated; MD, moderately differentiated; IALN, intra-abdominal lymph node.